278 related articles for article (PubMed ID: 20598982)
21. Primary prevention of sudden cardiac death: can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian sub-study.
Boriani G; Biffi M; Russo M; Lunati M; Botto G; Proclemer A; Vergara G; Rahue W; Martignani C; Ricci R; Santini M;
Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S29-34. PubMed ID: 17169130
[TBL] [Abstract][Full Text] [Related]
22. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
23. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
24. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
Das M
Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
[TBL] [Abstract][Full Text] [Related]
26. The implantable cardioverter-defibrillator: does everybody need one?
Raj SR; Sheldon RS
Prog Cardiovasc Dis; 2001; 44(3):169-94. PubMed ID: 11727276
[TBL] [Abstract][Full Text] [Related]
27. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.
Proclemer A; Ghidina M; Cicuttini G; Gregori D; Fioretti PM
Ital Heart J; 2005 Mar; 6(3):272-80. PubMed ID: 15875520
[TBL] [Abstract][Full Text] [Related]
28. Preventing sudden death: implantable cardioverter-defibrillators in elderly cardiac patients.
Groeneveld PW
LDI Issue Brief; 2008; 13(6):1-4. PubMed ID: 18613344
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
30. The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.
Henyan NN; White CM; Gillespie EL; Smith K; Coleman CI; Kluger J
J Intern Med; 2006 Nov; 260(5):467-73. PubMed ID: 17040253
[TBL] [Abstract][Full Text] [Related]
31. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of the implantable cardioverter defibrillator.
Hlatky MA; Sanders GD; Owens DK
Card Electrophysiol Rev; 2003 Dec; 7(4):479-82. PubMed ID: 15071279
[TBL] [Abstract][Full Text] [Related]
33. Benefits of the implantable cardioverter-defibrillator.
Epstein AE
J Am Coll Cardiol; 2008 Sep; 52(14):1122-7. PubMed ID: 18804737
[TBL] [Abstract][Full Text] [Related]
34. Should the implantable cardiac defibrillator be used for primary prevention of sudden death? A review of the issues relevant to hospital decision making.
McGregor M; Chen J
Can J Cardiol; 2004 Oct; 20(12):1199-204. PubMed ID: 15494771
[TBL] [Abstract][Full Text] [Related]
35. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
[TBL] [Abstract][Full Text] [Related]
36. Lack of current implantable cardioverter defibrillator guidelines application for primary prevention of sudden cardiac death in Latin American patients with heart failure: a cross-sectional study.
Gonzalez-Zuelgaray J; Pellizon O; Muratore CA; Oropeza ES; Rabinovich R; Ramos JL; Tentori MC; Reyes N; Aguayo R; Marin J; Peterson BJ
Europace; 2013 Feb; 15(2):236-42. PubMed ID: 22968848
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).
Gandjour A; Holler A; Dipl-Ges-Ök ; Adarkwah CC
Value Health; 2011; 14(6):812-7. PubMed ID: 21914500
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA.
O'Day K; Levy WC; Johnson M; Jacobson AF
Appl Health Econ Health Policy; 2016 Jun; 14(3):361-73. PubMed ID: 26975999
[TBL] [Abstract][Full Text] [Related]
39. The cost of implantable defibrillators: perceptions and reality.
Camm J; Klein H; Nisam S
Eur Heart J; 2007 Feb; 28(4):392-7. PubMed ID: 16887857
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of implantable defibrillators in octogenarians and nonagenarians for primary prevention of sudden cardiac death.
Mezu U; Adelstein E; Jain S; Saba S
Am J Cardiol; 2011 Sep; 108(5):718-22. PubMed ID: 21640321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
